In the latest session, Gritstone Bio Inc (NASDAQ: GRTS) closed at $0.84 down -8.78% from its previous closing price of $0.92. On the day, 4302309 shares were traded.
Ratios:
For a deeper understanding of Gritstone Bio Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.20 and its Current Ratio is at 3.20. In the meantime, Its Debt-to-Equity ratio is 2.02 whereas as Long-Term Debt/Eq ratio is at 1.89.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, JMP Securities on February 28, 2024, initiated with a Mkt Outperform rating and assigned the stock a target price of $4.
On March 28, 2023, B. Riley Securities started tracking the stock assigning a Buy rating and target price of $8.B. Riley Securities initiated its Buy rating on March 28, 2023, with a $8 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on May 23 ’23 when Economides Vassiliki bought 12,000 shares for $1.90 per share. The transaction valued at 22,829 led to the insider holds 214,058 shares of the business.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 67.29 while its Price-to-Book (P/B) ratio in mrq is 1.58.
Stock Price History:
Over the past 52 weeks, GRTS has reached a high of $3.33, while it has fallen to a 52-week low of $0.92.
Shares Statistics:
A total of 97.59M shares are outstanding, with a floating share count of 97.27M. Insiders hold about 8.58% of the company’s shares, while institutions hold 35.49% stake in the company.
Earnings Estimates
There are Tema Cardiovascular and Metabol different market analysts currently analyzing its stock. The consensus estimate for the next quarter is $0.84, with high estimates of $225.63 and low estimates of $6.56.
Analysts are recommending an EPS of between $Financial Services and $Healthcare for the fiscal current year, implying an average EPS of $Healthcare.
